Photo by brina_blum from unsplash
Immunoglobulin replacement has been standard therapy for patients with primary immunodeficiency diseases (PIDD). Intravenous immunoglobin (IVIg) is delivered at the hospital, whereas subcutaneous immunoglobin (SCIg) is used for home‐based treatment.… Click to show full abstract
Immunoglobulin replacement has been standard therapy for patients with primary immunodeficiency diseases (PIDD). Intravenous immunoglobin (IVIg) is delivered at the hospital, whereas subcutaneous immunoglobin (SCIg) is used for home‐based treatment. The aim of the study was to determine the advantages and disadvantages of IVIg and SCIg in Polish children aged 1–5 years, with PIDD, and the satisfaction of their parents / caregivers regarding immunoglobulin replacement.
Journal Title: Pediatrics International
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!